Radiotherapy and radiation oncology play a key role in the clinical management of patients
suffering from oncological diseases. In clinical routine, anatomic imaging such as contrast …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

Purpose Quantitative prostate-specific membrane antigen (PSMA) PET analysis may
provide for non-invasive and objective risk stratification of primary prostate cancer (PCa) …

Approaches and techniques used for diagnostic prostate biopsy have undergone
considerable evolution over the past few decades: from the original finger-guided …

Purpose Risk classification of primary prostate cancer in clinical routine is mainly based on
prostate-specific antigen (PSA) levels, Gleason scores from biopsy samples, and tumor …

Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific
membrane antigen (PSMA) in vivo, which is the target molecule of 177Lu-PSMA-617 (Lu …

In prostate cancer (PCa), the use of new radiopharmaceuticals has improved the accuracy of
diagnosis and staging, refined surveillance strategies, and introduced specific and …

After prostate malignancy diagnosis, precise determination of disease extent are
fundamental steps for tailored made therapy. The earlier the diagnosis of the burden of the …

Molecular imaging is a key tool in the diagnosis and treatment of prostate cancer (PCa).
Magnetic Resonance (MR) plays a major role in this respect with nuclear medicine imaging …

Purpose To evaluate the performance of combined PET and multiparametric MRI (mpMRI)
radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary …